Magazine Article | January 2, 2019

Companies To Watch: Synspira

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Fighting lung infection, inflammation, and congestion in the new glycomics space.

Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. The inhaled drugs are designed to enhance or restore the protective, antimicrobial properties of the glycocalyx, a layer of sugar molecules coating cells, an important constituent of mucus, and the first defensive barrier of innate immunity. When the glycocalyx is damaged or disrupted, harmful bacteria thrive and form obstructive biofilms involved in multiple maladies. The company’s products appear to help kill bacteria, break up the biofilm for the lungs to expel, and thereby increase antibiotic effectiveness.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader